Ascletis Pharma Inc.

Investors

2026

2025

2024

2023

2022

2021

2020

2019

2018

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2026
2026-04-08
Voluntary Announcement - Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development
2026-04-07
Annual Results Announcement for the Year Ended December 31, 2025 and Change in the Use of Proceeds
2026-03-31
Notice of Board Meeting
2026-03-18
Voluntary Announcement - Oral Small Molecule Amylin Receptor Agonist ASC39 Demonstrated Eloralintide-Like Amylin Selectivity and Efficacy in Preclinical Models
2026-03-17
Voluntary Announcement - Ascletis Announces Positive Topline Results from U.S. Phase II, 24-Week Study for Its Ultra-Long-Acting Subcutaneous Depot Formulations of Small Molecule GLP-1R Agonist ASC30 for Obesity
2026-03-10
Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2026
2026-03-03
Voluntary Announcement - Ascletis Selects Oral Amylin Receptor Peptide Agonist, ASC36, for Clinical Development
2026-02-11
Next Day Disclosure Returns - Others
2026-02-10
Completion of Placing of New Shares under the General Mandate
2026-02-10

1

© 2018 Ascletis Pharma Inc. All Rights Reserved
浙公网安备 33010802003344号浙ICP备11050387号-1